Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS NASDAQ:LNTH NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$363.28-0.3%$337.61$130.50▼$382.54$10.74B0.5563,927 shs355,895 shsLNTHLantheus$100.00-2.6%$103.93$47.25▼$111.86$6.68B-0.06794,892 shs1.56 million shsSRPTSarepta Therapeutics$15.53+0.6%$17.06$14.68▼$25.32$1.63B0.213.01 million shs2.86 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech-0.26%+7.86%-3.93%+38.52%+138.87%LNTHLantheus-2.57%-4.41%-8.74%+18.18%+38.50%SRPTSarepta Therapeutics+0.65%-1.83%-8.75%-25.62%-1.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$363.28-0.3%$337.61$130.50▼$382.54$10.74B0.5563,927 shs355,895 shsLNTHLantheus$100.00-2.6%$103.93$47.25▼$111.86$6.68B-0.06794,892 shs1.56 million shsSRPTSarepta Therapeutics$15.53+0.6%$17.06$14.68▼$25.32$1.63B0.213.01 million shs2.86 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech-0.26%+7.86%-3.93%+38.52%+138.87%LNTHLantheus-2.57%-4.41%-8.74%+18.18%+38.50%SRPTSarepta Therapeutics+0.65%-1.83%-8.75%-25.62%-1.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 2.83Moderate Buy$360.67-0.72% DownsideLNTHLantheus 2.73Moderate Buy$109.719.71% UpsideSRPTSarepta Therapeutics 2.14Hold$24.7259.19% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, KRYS, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/29/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$120.00 ➝ $115.007/28/2026SRPTSarepta Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/20/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)7/16/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $125.007/15/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform ➝ Market Outperform$115.00 ➝ $120.007/14/2026KRYSKrystal Biotech Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$364.00 ➝ $396.007/13/2026KRYSKrystal Biotech Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$474.007/9/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$97.00 ➝ $129.007/9/2026SRPTSarepta Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$23.00 ➝ $20.007/9/2026SRPTSarepta Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$27.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$389.13M27.52$7.27 per share49.97$42.06 per share8.64LNTHLantheus$1.55B4.21$6.22 per share16.07$16.43 per share6.09SRPTSarepta Therapeutics$2.20B0.75N/AN/A$10.89 per share1.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$204.83M$7.4848.5739.06N/A53.92%19.25%17.62%8/3/2026 (Estimated)LNTHLantheus$233.56M$4.1524.1018.59N/A18.05%29.32%15.00%8/5/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A7.960.17-2.94%7.56%2.94%8/5/2026 (Estimated)Latest SRPT, KRYS, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026LNTHLantheus$1.33N/AN/AN/A$362.45 millionN/A8/5/2026Q2 2026SRPTSarepta Therapeutics$0.4861N/AN/AN/A$366.39 millionN/A8/3/2026Q2 2026KRYSKrystal Biotech$1.70N/AN/AN/A$121.83 millionN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.469.06LNTHLantheus0.472.832.64SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%LNTHLantheus99.06%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.10%LNTHLantheus1.70%SRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableSRPT, KRYS, and LNTH HeadlinesRecent News About These CompaniesSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages2 hours ago | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Brokerages2 hours ago | marketbeat.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 29 at 7:58 PM | finance.yahoo.comEarnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to DeclineJuly 29 at 2:57 PM | finance.yahoo.comEarnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to DeclineJuly 29 at 11:02 AM | zacks.comSarepta Therapeutics (SRPT) Projected to Release Quarterly Earnings on WednesdayJuly 29 at 8:25 AM | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Healthcare of Ontario Pension Plan Trust FundJuly 29 at 5:27 AM | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Purchased by Renaissance Technologies LLCJuly 29 at 5:19 AM | marketbeat.comADAR1 Capital Management LLC Has $5.70 Million Holdings in Sarepta Therapeutics, Inc. $SRPTJuly 29 at 3:03 AM | marketbeat.comLeadership changes afoot at two CGT biotechsJuly 28 at 12:31 PM | pharmaceutical-technology.comPMorgan Stanley views Sarepta CEO transition as a 'positive' – so, why is it cautious on SRPT stock in the near term?July 28 at 7:30 AM | msn.comMorgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term?July 27 at 3:11 PM | stocktwits.comSSarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive OfficerJuly 27 at 10:11 AM | finance.yahoo.comSarepta Therapeutics Appoints Michael Severino as CEOJuly 27 at 9:30 AM | tipranks.comSarepta names former Abbvie president as CEO as Ingram retiresJuly 27 at 9:19 AM | reuters.comSarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive OfficerJuly 27 at 9:00 AM | businesswire.comFirst Trust Advisors LP Boosts Stock Position in Sarepta Therapeutics, Inc. $SRPTJuly 25, 2026 | marketbeat.comIs Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?July 23, 2026 | trefis.comTSarepta Therapeutics to Announce Second Quarter 2026 Financial ResultsJuly 22, 2026 | finance.yahoo.comSRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?July 22, 2026 | finance.yahoo.comSRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?July 22, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRPT, KRYS, and LNTH Company DescriptionsKrystal Biotech NASDAQ:KRYS$363.28 -0.95 (-0.26%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$365.65 +2.37 (+0.65%) As of 04:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Lantheus NASDAQ:LNTH$100.00 -2.64 (-2.57%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$99.70 -0.30 (-0.30%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$15.53 +0.10 (+0.65%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$15.52 -0.01 (-0.10%) As of 04:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
